Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRF2105 patch in osteoarthritis
NCT06047483Phase 2Not yet recruiting
- Sponsor
- Hengrui
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of HRF-2105 in osteoarthritis (OA) (3 arms), sponsored by Hengrui. Primary endpoint: Change in Visual Analog Scale score on rising from the chair at Day 7. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
HRF-2105
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06047483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047483.